Lang A, Harro J, Soosaar A, Kõks S, Volke V, Oreland L, Bourin M, Vasar E, Bradwejn J, Männistö P T
Institute of Physiology, Tartu University, Estonia.
Naunyn Schmiedebergs Arch Pharmacol. 1995 Apr;351(4):363-70. doi: 10.1007/BF00169076.
We studied the aggressive behaviour induced by repeated treatment with apomorphine, a dopamine agonist (0.5 mg/kg s.c. twice daily, 10 days), in rats. The first signs of defensive aggressiveness appeared on the third day of apomorphine treatment and were generally seen on the 7th day. Aggressiveness induced by a challenge dose of apomorphine (0.5 mg/kg s.c.) on the 11th day was antagonized by haloperidol (0.05 and 0.1 mg/kg i.p.) and clozapine (10 mg/kg i.p.). An antagonist of N-methyl-D-aspartate (NMDA)-gated channels, dizocilpine (MK-801), also blocked the aggressive behaviour at 0.25 and 0.5 mg/kg i.p. but caused ataxia. When dizocilpine (0.25 mg/kg i.p.) and apomorphine were coadministered for 10 days, aggressive behaviour did not develop. At 0.025 mg/kg i.p., dizocilpine even accelerated the appearance of apomorphine-induced aggressive behaviour, which manifested on the 3rd day in all rats. In a separate study, a 7-day treatment with dizocilpine (0.25-1 mg/kg i.p.) of rats, sensitized by a prior 10-day apomorphine treatment, did not reverse the established aggressive behaviour. The coadministration of apomorphine and cholecystokinin (CCK) -A or -B antagonists, devazepide or L-365,260 (0.01-2.5 mg/kg i.p.) respectively, neither affected development of apomorphine-induced aggressive behaviour nor intensity of aggressiveness in the sensitized rats. In binding studies neither density nor affinity of striatal dopamine D2 receptors was changed by acute or chronic apomorphine treatment. The number of [3H]pCCK-8 binding sites in the frontal cortex increased already after a single injection of apomorphine.(ABSTRACT TRUNCATED AT 250 WORDS)
我们研究了多巴胺激动剂阿扑吗啡(0.5毫克/千克,皮下注射,每日两次,共10天)反复给药诱导大鼠的攻击行为。防御性攻击的最初迹象出现在阿扑吗啡治疗的第三天,通常在第7天出现。第11天,阿扑吗啡激发剂量(0.5毫克/千克,皮下注射)诱导的攻击行为被氟哌啶醇(0.05和0.1毫克/千克,腹腔注射)和氯氮平(10毫克/千克,腹腔注射)拮抗。N-甲基-D-天冬氨酸(NMDA)门控通道拮抗剂地佐环平(MK-801)在0.25和0.5毫克/千克腹腔注射时也能阻断攻击行为,但会导致共济失调。当地佐环平(0.25毫克/千克,腹腔注射)和阿扑吗啡联合给药10天时,未出现攻击行为。地佐环平在0.025毫克/千克腹腔注射时,甚至加速了阿扑吗啡诱导的攻击行为的出现,所有大鼠在第3天就表现出该行为。在另一项研究中,对先前经10天阿扑吗啡治疗致敏的大鼠,用地佐环平(0.25 - 1毫克/千克,腹腔注射)进行7天治疗,并未逆转已形成的攻击行为。阿扑吗啡与胆囊收缩素(CCK)-A或 -B拮抗剂分别为地伐西匹或L-365,260(0.01 - 2.5毫克/千克,腹腔注射)联合给药,既不影响阿扑吗啡诱导的攻击行为的发展,也不影响致敏大鼠的攻击强度。在结合研究中,急性或慢性阿扑吗啡治疗均未改变纹状体多巴胺D2受体的密度或亲和力。单次注射阿扑吗啡后,额叶皮质中[3H]pCCK-8结合位点的数量就已增加。(摘要截断于250字)